New Patents Database To Help Countries Improve Medicines Procurement

The international drug industry group, IFPMA, the World Intellectual Property Organization and 20 big pharmas have launched Pat-INFORMED, a new patent database that can be used by governments to improve their medicines procurement programs. The R&D-based industry says it clearly links public patent information to registered medicines in a new, user-friendly online gateway. However, the European generics industry body Medicines For Europe says the move amounts to "patent linkage" and will have anti-competitive effects for generics firms. 

Procurement
The Pat-INFORMED initiative is meant to help drug procurement agencies around the world • Source: Shutterstock

A new global tool has been launched to help procurement agencies more easily assess patent status and thereby improve the way they purchase medicines, for example by allowing them to quickly ascertain whether they can lawfully obtain a generic medicine without infringing a patent.

The open-access Patent Information Initiative for Medicines (Pat-INFORMED) contains data on more than 14,000 individual patents, 600 patent families and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Products

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

 
• By 

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By 

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.